|AVM Biotechnology LLC, of Seattle||AVM-0703||Formulation of high concentration of dexamethasone||Acute respiratory distress syndrome mediated by COVID-19 or influenza||FDA cleared the IND|
|Cura Foundation, of New York||hCT-MSC||Human cord tissue mesenchymal stromal cells||Multisystem inflammatory syndrome in children||FDA approved the IND; study to begin in September|
|Mateon Therapeutics, of Agoura Hills, Calif.||Oxi-4503||Cis-combretastatin A1 dipotassium diphosphate||Acute myeloid leukemia||FDA granted rare pediatric disease designation|
|Mediwound Ltd., of Yavne, Israel||Nexobrid||Proteolytic enzymes enriched in bromelain||Eschar removal in deep partial-thickness and/or full-thickness thermal burns||FDA accepted the BLA; PDUFA target action date is June 29, 2021|
|Orphazyme A/S, of Copenhagen||Arimoclomol||Chaperonin/Hsp70 stimulator||Niemann-Pick disease type C||FDA accepted the NDA and granted a priority review; PDUFA target action date is March 17, 2021|
For more information about individual companies and/or products, see Cortellis.